Metsera, Inc. (NASDAQ:MTSR – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $32.33 and last traded at $32.19, with a volume of 70254 shares changing hands. The stock had previously closed at $30.58.
Metsera Stock Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
- Five stocks we like better than Metsera
- Short Selling: How to Short a Stock
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What is the FTSE 100 index?
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
